Vertex Pharmaceuticals Incorporated (VRTX) Announces Presentation of Data at European Cystic Fibrosis Society Conference
6/5/2013 9:34:08 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that six abstracts from its cystic fibrosis (CF) program will be presented at the 36th European Cystic Fibrosis Society (ECFS) Conference in Lisbon, Portugal, June 12 to 15, 2013. Presentations include data from Cohorts 2 and 3 of a Phase 2 study of lumacaftor (VX-809) combined with ivacaftor in people with the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, F508del, as well as data from a Phase 2 study of VX-661 combined with ivacaftor in people with two copies of the F508del mutation. Additionally, poster presentations will feature data on the use of KALYDECO™ (ivacaftor) in people with CF ages 6 and older who have the G551D mutation.
Help employers find you! Check out all the jobs and post your resume.